Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ATHX's Cash to Debt is ranked higher than
88% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. ATHX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATHX' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.77
ATHX's Equity to Asset is ranked higher than
60% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ATHX: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
ATHX' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.66 Max: 0.93
Current: 0.77
0.19
0.93
Interest Coverage N/A
ATHX's Interest Coverage is ranked lower than
54% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ATHX: N/A )
Ranked among companies with meaningful Interest Coverage only.
ATHX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.00 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 5
Z-Score: 2.38
M-Score: 11.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13.37
ATHX's Operating margin (%) is ranked higher than
64% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. ATHX: -13.37 )
Ranked among companies with meaningful Operating margin (%) only.
ATHX' s Operating margin (%) Range Over the Past 10 Years
Min: -1787.55  Med: -399.32 Max: -0.05
Current: -13.37
-1787.55
-0.05
Net-margin (%) 3.04
ATHX's Net-margin (%) is ranked higher than
73% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. ATHX: 3.04 )
Ranked among companies with meaningful Net-margin (%) only.
ATHX' s Net-margin (%) Range Over the Past 10 Years
Min: -1360.57  Med: -374.33 Max: -0.05
Current: 3.04
-1360.57
-0.05
ROE (%) 4.01
ATHX's ROE (%) is ranked higher than
80% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. ATHX: 4.01 )
Ranked among companies with meaningful ROE (%) only.
ATHX' s ROE (%) Range Over the Past 10 Years
Min: -176.55  Med: -106.99 Max: -45.44
Current: 4.01
-176.55
-45.44
ROA (%) 2.45
ATHX's ROA (%) is ranked higher than
81% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ATHX: 2.45 )
Ranked among companies with meaningful ROA (%) only.
ATHX' s ROA (%) Range Over the Past 10 Years
Min: -99.51  Med: -64.01 Max: -0.09
Current: 2.45
-99.51
-0.09
ROC (Joel Greenblatt) (%) -295.93
ATHX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ATHX: -295.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATHX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4646.21  Med: -1644.96 Max: -0.78
Current: -295.93
-4646.21
-0.78
Revenue Growth (3Y)(%) -18.60
ATHX's Revenue Growth (3Y)(%) is ranked lower than
72% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ATHX: -18.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATHX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -37.00 Max: 39.5
Current: -18.6
0
39.5
EBITDA Growth (3Y)(%) -22.80
ATHX's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ATHX: -22.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATHX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.30 Max: 384.7
Current: -22.8
0
384.7
EPS Growth (3Y)(%) -23.90
ATHX's EPS Growth (3Y)(%) is ranked lower than
73% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ATHX: -23.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATHX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.45 Max: 445.6
Current: -23.9
0
445.6
» ATHX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

ATHX Guru Trades in Q1 2015

Ronald Muhlenkamp 10,150 sh (New)
First Eagle Investment 807,601 sh (+13.35%)
First Eagle Investment 2,500 sh (unchged)
» More
Q2 2015

ATHX Guru Trades in Q2 2015

First Eagle Investment Sold Out
Ronald Muhlenkamp Sold Out
» More
Q4 2015

ATHX Guru Trades in Q4 2015

Jim Simons 112,834 sh (New)
» More
Q1 2016

ATHX Guru Trades in Q1 2016

Jim Simons 343,034 sh (+204.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:MXDHF, NAS:IMDZ, OTCPK:RCAR, NAS:AVXL, NAS:CDXS, OTCPK:CTIX, AMEX:AMPE, NAS:ZFGN, NAS:CMRX, OTCPK:SPHRY, NAS:MDWD, NAS:AKTX, OTCPK:RNUGF, NAS:CYTR, NYSE:EVGN, AMEX:PIP, OTCPK:VRACY, NAS:DMTX, AMEX:SYN, NAS:OSIR » details
Traded in other countries:4LS.Germany,
Athersys Inc is a biopharmaceutical company developing regenerative medicine. It is engaged in the discovery and development of therapies designed to extend and enhance human life.

Athersys Inc was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The Companys current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. Its partner, Pfizer Inc. is conducting Phase 2 clinical study of MultiStem cells. Myocardial infarction is one of the causes of death and disability in the United States. The Company is engaged in five programs including, Inflammatory Bowel Disease; Ischemic Stroke; Acute Myocardial Infarction; Hematopoietic Stem Cell Transplant / GvHD; Multistem. The Company partners with Pfizer, RTI, Angiotech and Bristol-Myers Squibb. It competes with Stem Cells Inc., Johnson & Johnson, Celgene Corporation, or Celgene, Advanced Cell Technology, Inc. The Company has 36 issued patents; 16 United States and 20 international. The Company and its related programs and the products are subject to government regulations.

Ratios

vs
industry
vs
history
PE(NRI) 196.00
ATHX's PE(NRI) is ranked lower than
92% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. ATHX: 196.00 )
Ranked among companies with meaningful PE(NRI) only.
ATHX' s PE(NRI) Range Over the Past 10 Years
Min: 178  Med: 227.00 Max: 263
Current: 196
178
263
P/B 6.43
ATHX's P/B is ranked lower than
74% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ATHX: 6.43 )
Ranked among companies with meaningful P/B only.
ATHX' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 4.36 Max: 23.38
Current: 6.43
0.18
23.38
P/S 6.12
ATHX's P/S is ranked higher than
65% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. ATHX: 6.12 )
Ranked among companies with meaningful P/S only.
ATHX' s P/S Range Over the Past 10 Years
Min: 1.15  Med: 8.14 Max: 152.38
Current: 6.12
1.15
152.38
Current Ratio 6.68
ATHX's Current Ratio is ranked higher than
63% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ATHX: 6.68 )
Ranked among companies with meaningful Current Ratio only.
ATHX' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 6.68
0.47
12.58
Quick Ratio 6.68
ATHX's Quick Ratio is ranked higher than
65% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ATHX: 6.68 )
Ranked among companies with meaningful Quick Ratio only.
ATHX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 6.68
0.47
12.58
Days Sales Outstanding 9.66
ATHX's Days Sales Outstanding is ranked higher than
89% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ATHX: 9.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATHX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.03  Med: 68.68 Max: 156.08
Current: 9.66
11.03
156.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.26
ATHX's Price/Net Cash is ranked lower than
59% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. ATHX: 7.26 )
Ranked among companies with meaningful Price/Net Cash only.
ATHX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.33  Med: 6.02 Max: 23
Current: 7.26
0.33
23
Price/Net Current Asset Value 6.76
ATHX's Price/Net Current Asset Value is ranked lower than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. ATHX: 6.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATHX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.32  Med: 5.78 Max: 69.5
Current: 6.76
0.32
69.5
Price/Tangible Book 6.53
ATHX's Price/Tangible Book is ranked lower than
66% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. ATHX: 6.53 )
Ranked among companies with meaningful Price/Tangible Book only.
ATHX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.27  Med: 4.42 Max: 21.38
Current: 6.53
0.27
21.38
Price/Median PS Value 0.75
ATHX's Price/Median PS Value is ranked higher than
64% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. ATHX: 0.75 )
Ranked among companies with meaningful Price/Median PS Value only.
ATHX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 0.99 Max: 16.94
Current: 0.75
0.18
16.94
Price/Graham Number 7.54
ATHX's Price/Graham Number is ranked lower than
83% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 3.09 vs. ATHX: 7.54 )
Ranked among companies with meaningful Price/Graham Number only.
ATHX' s Price/Graham Number Range Over the Past 10 Years
Min: 8.65  Med: 8.65 Max: 8.65
Current: 7.54
Earnings Yield (Greenblatt) (%) -2.60
ATHX's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ATHX: -2.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATHX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.6  Med: 206.20 Max: 17247.5
Current: -2.6
-2.6
17247.5

More Statistics

Revenue (TTM) (Mil) $26.68
EPS (TTM) $ -0.03
Beta-0.94
Short Percentage of Float6.92%
52-Week Range $0.94 - 2.90
Shares Outstanding (Mil)84.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 16 1 1
EPS ($) -0.20 -0.24 -0.21
EPS w/o NRI ($) -0.20 -0.24 -0.21
EPS Growth Rate
(3Y to 5Y Estimate)
N/A

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)